

Supplemental Table 1. Prevalence, pharmacologic treatment, and control of hypertension among US non-pregnant women of reproductive age^a

Characteristic	<i>n</i>	% (95% CI)
2003 JNC 7 Guidelines		
Hypertension ^b	483	9.0 (8.1, 9.9)
Eligible for pharmacologic treatment ^c	483	100.0 (100.0, 100.0)
Current use of BP-lowering medication ^d	299	64.8 (60.1, 69.5)
BP control ^e	201	47.1 (42.4, 51.9)
BP control among those using medication ^e	201	72.7 (67.4, 78.1)
2017 ACC/AHA Guidelines		
Hypertension ^f	961	19.3 (17.7, 20.9)
Eligible for pharmacologic treatment ^g	566	54.5 (50.3, 58.7)
Current use of BP-lowering medication ^h	299	55.5 (51.5, 59.9)
BP control ⁱ	146	16.1 (13.4, 18.8)
BP control among those using medication ⁱ	146	53.1 (46.4, 59.7)

Abbreviations: ACC, American College of Cardiology; AHA, American Heart Association; BP, blood pressure; JNC 7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

- Data are from the National Health and Nutrition Examination Survey, 2011–March 2020, women aged 20–44 years ($n=4,590$). Ns are unweighted. Values are % (95% CI). Prevalence estimates are weighted and account for complex design.
- Hypertension defined as systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg or self-reported current use of BP-lowering medication (JNC 7 2003).
- Eligibility for guideline-recommended pharmacologic treatment defined as self-reported current use of BP-lowering medication, systolic BP ≥ 130 mmHg or diastolic BP ≥ 80 mmHg among those with diabetes or chronic kidney disease, and systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg among all other women

(JNC 7 2003). According to the JNC 7 guidance, all women with hypertension were eligible for guideline-recommended pharmacologic treatment.

- d) Among those with hypertension who were eligible for guideline-recommended pharmacologic treatment per 2003 JNC 7 ($n=483$).
- e) Blood pressure control defined as systolic BP <130 and diastolic BP <80 mmHg among those with hypertension and diabetes or chronic kidney disease and systolic BP <140 mmHg and diastolic BP <90 mmHg among all other women with hypertension per 2003 JNC 7.
- f) Hypertension defined as systolic BP ≥ 130 mmHg or diastolic BP ≥ 80 mmHg or self-reported current use of BP-lowering medication (AHA/ACC 2017).
- g) Eligibility for guideline-recommended pharmacologic treatment defined as self-reported current use of BP-lowering medication, systolic BP ≥ 130 mmHg or diastolic BP ≥ 80 mmHg among women with diabetes, chronic kidney disease, or high risk of cardiovascular disease, or systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg among all other women (AHA/ACC 2017).
- h) Among those with hypertension who were eligible for guideline-recommended pharmacologic treatment per 2017 ACC/AHA ($n=528$).
- i) Blood pressure control defined as systolic BP <130 mmHg and diastolic BP <80 mmHg among those with hypertension per 2017 ACC/AHA.

Supplemental Table 2. Hypertension among US non-pregnant women of reproductive age 18-44y by race/Hispanic origin^a, National Health and Nutrition Examination Survey, 2011–March 2020 (*n*=4,590)

	Hispanic (<i>n</i> =1,160)		NH Black (<i>n</i> =1,101)		NH White (<i>n</i> =1,491)		Another or multiple NH races ^b (<i>n</i> =838)		
Characteristic	<i>n</i>	% (95% CI)	<i>n</i>	% (95% CI)	<i>n</i>	% (95% CI)	<i>n</i>	% (95% CI)	<i>P</i> ^c
2003 JNC 7 Guidelines									
Hypertension ^d	90	7.1 (5.8,8.4)	207	18.3 (16.0,20.7)	127	7.7 (6.4,9.1)	59	7.3 (4.9,9.6)	<0.0001
Eligible for pharmacologic treatment ^e	90	100.0 (100.0,100.0)	207	100.0 (100.0,100.0)	127	100.0 (100.0,100.0)	59	100.0 (100.0,100.0)	-
Current use of BP-lowering medication ^f	55	59.1 (47.1,71.1)	123	58.4 (50.6,66.2)	92	72.4 (64.3,80.4)	29	52.3 (37.7,67.0)	0.01
BP control ^g	45	46.0 (35.5,56.5)	71	36.1 (29.0,43.3)	67	54.9 (46.3,63.6)	18	39.8 (25.5,54.0)	0.004
BP control among those using medication ^g	45	77.9 (67.1,88.6)	71	61.9 (53.1,70.7)	67	75.9 (66.6,85.2)	18	76.0 (61.3,90.8)	0.09
2017 ACC/AHA Guidelines									
Hypertension ^h	175	14.0 (12.0,15.9)	351	30.9 (27.8,34.0)	290	18.5 (16.2,20.8)	145	18.2 (13.9,22.6)	<0.0001

Eligible for pharmacologic treatment ⁱ	112	62.8 (55.4,70.3)	231	65.5 (60.4,70.5)	150	48.9 (43.2,54.6)	73	49.7 (40.4,59.0)	<0.0001
Current use of BP-lowering medication ^j	55	47.9 (36.9,58.9)	123	52.9 (45.7,60.2)	92	61.8 (53.8,69.9)	29	42.0 (28.1,55.8)	0.03
BP control ^k	36	18.6 (12.1,25.0)	49	14.4 (11.2,17.5)	53	18.0 (13.5,22.5)	8	5.2 (1.1,9.3) ^l	0.007
BP control among those using medication ^k	36	61.7 (47.9,75.5)	49	41.5 (33.9,49.1)	53	59.6 (49.4,69.8)	8	25.0 (3.9,46.1) ^l	0.002

Abbreviations: ACC, American College of Cardiology; AHA, American Heart Association; BP, blood pressure; NH, non-Hispanic.

- a) Data are from the National Health and Nutrition Examination Survey, 2011–March 2020. Ns are unweighted. Values are % (95% CI). Prevalence estimates are weighted and account for complex design.
- b) Another or multiple non-Hispanic races includes non-Hispanic Asian, Native Hawaiian, Pacific Islander, American Indian, Alaskan Native, and people identifying with more than one race.
- c) *P* values calculated for Rao-Scott chi-square tests.
- d) Hypertension defined as systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg or self-reported current use of BP-lowering medication (JNC 7 2003).
- e) Eligibility for guideline-recommended pharmacologic treatment defined as self-reported current use of BP-lowering medication, systolic BP ≥ 130 mmHg or diastolic BP ≥ 80 mmHg among those with diabetes or chronic kidney disease, and systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg among all other women (JNC 7 2003). According to the JNC 7 guidance, all women with hypertension were eligible for guideline-recommended pharmacological treatment.
- f) Among those with hypertension who were eligible for guideline-recommended pharmacologic treatment per 2003 JNC 7.

- g) Blood pressure control defined as systolic BP <130 and diastolic BP <80 mmHg among those with hypertension and diabetes or chronic kidney disease and systolic BP <140 mmHg and diastolic BP <90 mmHg among all other women with hypertension per 2003 JNC 7.
- h) Hypertension defined as systolic BP \geq 130 mmHg or diastolic BP \geq 80 mmHg or self-reported current use of BP-lowering medication (AHA/ACC 2017).
- i) Eligibility for guideline-recommended pharmacologic treatment defined as self-reported current use of BP-lowering medication, systolic BP \geq 130 mmHg or diastolic BP \geq 80 mmHg among women with diabetes, chronic kidney disease, or high risk of cardiovascular disease, or systolic BP \geq 140 mmHg or diastolic BP \geq 90 mmHg among all other women (AHA/ACC 2017).
- j) Among those with hypertension who were eligible for guideline-recommended pharmacologic treatment per 2017 ACC/AHA.
- k) Blood pressure control defined as systolic BP <130 mmHg and diastolic BP <80 mmHg among those with hypertension per 2017 ACC/AHA.
- l) Interpret with caution. Estimate does not meet National Center for Health Statistics (NCHS) guidelines for reportability due to small denominator n.